BioCryst’s HAE med Orladeyo wins NICE nod
NICE has recommended the treatment for people who have at least two attacks per month
Read More
Tag: BioCryst
MHRA allows HAE patients early access to berotralstat
The oral, once-daily therapy is designed to prevent attacks and reduce burden of therapy
Read More
Five new medicines backed for EU approval
Five therapies have been backed for approval in the European Union, including two orphan medicines addressing rare conditions.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
